Press Releases

Date Title and Summary Additional Formats
Toggle Summary Innoviva to Participate in Baird Global Healthcare Conference on September 7
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer will participate in the 2017 Baird Global Healthcare
View HTML
Toggle Summary Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes
Closes $250 Million Term B Loan Refinancing plan expected to reduce the associated current cash interest expense by nearly one-half BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (" Innoviva" or the "Company") (NASDAQ: INVA) today announced the closing of a $250 million Term B Loan (the "Term
View HTML
Toggle Summary Innoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers' $17.5 million Over-Allotment Option
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced that it closed its offering of the Company's 2.50% convertible senior notes due 2025 (the "Notes") for gross proceeds of $192.5 million in aggregate principal.
View HTML
Toggle Summary Innoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced the pricing of $175 million aggregate principal amount of the Company's 2.50% convertible senior notes due 2025 (the "Notes"). The Notes will be sold in a private placement to qualified
View HTML
Toggle Summary Innoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced its intention to offer, subject to market conditions and other factors, $175 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement
View HTML
Toggle Summary Innoviva Reports Strong Second Quarter 2017 Financial Results
Royalties earned up 73% and net income up 141% compared to second quarter of 2016 Management to host a conference call and webcast today at 5:00 p.m. Eastern time BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter
View HTML
Toggle Summary GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) /
View HTML
Toggle Summary Innoviva to Report Second Quarter Financial Results on July 26 at 5:00 p.m. EDT
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the second quarter ended June 30, 2017 after market close on Wednesday, July 26, 2017 . Following the earnings release, Innoviva management will host a webcast and conference
View HTML
Toggle Summary Innoviva to Participate in Bank of America Merrill Lynch Healthcare Conference on May 17
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer, will participate in a fireside chat at the Bank of
View HTML
Toggle Summary Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care
Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care. LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive
View HTML

Copyright West LLC. Minimum 15 minutes delayed.

Contact

Toll-Free
877-202-1097

Innoviva Investor Relations & Media
Sloane and Company
212-446-9500

For business development inquiries,
please contact investor.relations@inva.com.